Previous 10 | Next 10 |
Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...
Bonso Electronics International ( BNSO ) +158% . MAGIC EMPIRE GLOBAL ( MEGL ) +101% . Karuna Therapeutics ( KRTX ) +50% as schizophrenia trial meets key goal. Bed Bath & Beyond ( BBBY ) +38% . Iveda Solutions ( IVDA ) +...
The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2022 Q2 - Results - Earnings Call Presentation
Cerevel Therapeutics Holdings, Inc. (CERE) Q2 2022 Earnings Conference Call August 01, 2022, 08:00 AM ET Company Participants Matt Calistri - Vice President of Corporate Strategy and Investor Relations Tony Coles - Chairperson and Chief Executive Officer Ray Sanc...
Cerevel Therapeutics press release ( NASDAQ: CERE ): Q2 GAAP EPS of -$0.61 misses by $0.13 . Cash, cash equivalents and marketable securities as of June 30, 2022, were $531.2 million, inclusive of $37.5M from the tavapadon risk-sharing arrangement received in April 202...
Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer’s disease psychosis Panic disorder selected as ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...
CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2022 financial results on Monday, August 1, ...
Cerevel is a CNS specialist drug developer formed as a result of a spinout of former Pfizer neuroscience assets. The company listed via a merger with a SPAC, which gave it ~$350m in funding, together with $150m raised privately. There are 3 lead assets - Emraclidine in schizophren...
Biopharmaceutical companies Athira Pharma ( ATHA ) and BioXcel Therapeutics ( BTAI ) have outperformed the gains in the biotech space on Thursday after Mizuho launched their coverage on small and mid-cap names focused on the central nervous system (CNS). Despite being a high...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are enco...